Last reviewed · How we verify
Bevacizumab (Avastin®)
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors need to grow.
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors need to grow. Used for Metastatic colorectal cancer (in combination with chemotherapy), Metastatic non-small cell lung cancer (in combination with chemotherapy), Metastatic breast cancer (in combination with paclitaxel).
At a glance
| Generic name | Bevacizumab (Avastin®) |
|---|---|
| Also known as | Avastin®, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF |
| Sponsor | Hanny Al-Samkari, MD |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
By binding to circulating VEGF, bevacizumab inhibits angiogenesis—the formation of new blood vessels that supply oxygen and nutrients to tumors. This starves cancer cells of their blood supply, slowing or stopping tumor growth. It is often combined with chemotherapy to enhance anti-tumor effects.
Approved indications
- Metastatic colorectal cancer (in combination with chemotherapy)
- Metastatic non-small cell lung cancer (in combination with chemotherapy)
- Metastatic breast cancer (in combination with paclitaxel)
- Glioblastoma (recurrent)
- Metastatic renal cell carcinoma (in combination with interferon-alpha)
- Persistent, recurrent, or metastatic cervical cancer (in combination with chemotherapy)
Common side effects
- Hypertension
- Proteinuria
- Hemorrhage (including severe/fatal)
- Thromboembolism
- Gastrointestinal perforation
- Wound healing complications
- Fatigue
- Diarrhea
- Nausea
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients (PHASE1, PHASE2)
- Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer (PHASE1, PHASE2)
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab (Avastin®) CI brief — competitive landscape report
- Bevacizumab (Avastin®) updates RSS · CI watch RSS
- Hanny Al-Samkari, MD portfolio CI